Evaluating Use of Empagliflozin for Diabetes Management in Veterans With Chronic Kidney Disease
Abstract
Background
About 1 in 4 veterans have diabetes, and many also have chronic kidney disease (CKD). Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, is approved for the treatment of diabetes. The purpose of this study was to evaluate the effectiveness of empagliflozin on hemoglobin A1c (HbA1c) in patients with CKD.
Methods
A retrospective chart review evaluated patients that had a type 2 diabetes diagnosis and stage 3 CKD prescribed empagliflozin for diabetes management between January 1, 2015, and October 1, 2022. Patient demographics, medication, HbA1c levels, and other data were collected from a random sample of 100 patients from 1771 potential study subjects.
Results
There was no statistically significant difference in changes in HbA1c levels between those with stage 3 and stage 3b diabetes CKD who were taking empagliflozin (P = .51). Within each group, there were significant statistical differences in changes in HbA1c for patients with stage 3a (P < .05) and stage 3b (P = .02). Patients with stage 3a had a reduction in HbA1c of 0.65% and the stage 3b grow had a 0.48% reduction. There was a statistically significant weight change for patients in the stage 3a group (P < .05). Statistically significant differences were found in systolic (P = .003) and diastolic (P = .04) blood pressure for the stage 3a CKD group only. The most common adverse effects leading to discontinuation of empagliflozin were dizziness, increased incidence of urinary tract infections,…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.